INTRODUCTION - Inventurus Knowledge Solutions Limited (IKS) is a prominent technology-enabled healthcare solutions provider, primarily serving physician enterprises across the United States, Canada, and Australia, with a major focus on the lucrative U.S. market.
The company was formed in Goa in 2006 by Sachin Gupta and ultimately was made public via an IPO in late 2022. The late, great Rakesh Jhunjhunwala is also a co-promoters of the company along with Sachin Gupta as RJ participated in prior private funding rounds.
Business Model and Service Offerings - IKS operates as a technology-enabled healthcare solutions provider, primarily assisting physician enterprises across outpatient and inpatient care organizations mainly in the United States. The fundamental objective of the company is to empower physicians by alleviating their administrative and operational burdens, thereby enabling them to concentrate more effectively on patient care.
In one line – It enables physicians to focus on the “Core” rather than “Chores”. This is quite a big deal because for every patient a physician sees in the clinic, they spend almost 15-20 minutes documenting & making clinical notes, sending prescriptions, validating procedure codes for billing etc. The physician’s office on the other hand must get insurance pre authorizations, schedule follow ups, the entire revenue cycle management apart from other administrative tasks.
It is estimated that about 15% of revenue of a physician’s office (PO) goes in accomplishing these tasks. IKS’s value proposition is simple – we will cut that to less than 10% of revenue through automation & free up more physician time so you can see more patients, therefore increase revenue as well, while working the same hours.
IKS currently has about 16 different products (technology solutions) that help a PO (Physician office) achieve these efficiency’s & cost savings. It sells these solutions either independently based on the need of the organization or altogether in one integrated platform.
The marketing strategy so far has been to start with one or two products to get its foot in the door and then cross sell the other tech / AI based solutions with the ultimate goal of selling the integrated EVE platform with all 16 modules.
IKS (Pre Aquity) had about 45 medium - large PO’s as clients (PO revenues >$250 Mn). Aquity on the other hand had about 800 PO’s out of which only 500 are medium to large, that’s what IKS plans to target. So the focus post this acquisition is to sell IKS’s suite of products and solutions to 500 out of the 800 new PO’s. That will be the the main growth driver going forward! not to mention that the market itself is growing at 10%-12%.
TAM & Market opportunity – IKS post the acquisition of Aquity has approximately 150,000 of the 900,000 physicians in the US captive. Meaning that they use at least 1 or more of IKS’s (or formerly Aquity’s) products/services. While the company lists the total TAM at $222 Bn growing at 9% CAGR, I am not so sure that is a good way to think about the TAM. Currently only $34Bn is the total outsourced TAM which includes all service RCM (Revenue Cycle Management), scribing etc. This is the market size of all services physicians offices actually outsource as of today. If we were to include hospitals along with PO’s the TAM would increase by another $50 Bn, so theoretically we can say that the total market size in the US alone is $84 Bn as of today, growing at a CARG of 10%-12%.
Products & Services - IKS distinguishes itself through its strong emphasis on technology solutions, that have been co-created alongside PO’s, doctors & medical administrators over the past 18 years. This is quite an important point, because most of the solutions developed have been specifically tailored to issues large PO’s (>$1Bn Revenue) were facing. Co-creating these solutions with them has led to a high level of customer stickiness & renewal rates (90%+ of revenues from existing customers) and high NPS score.
Historically, a majority of the solutions were tech enabled & Outsourcing (human) led, replacing workers in the US with workers in India. But recently, with the advent of AI this has changed from a tech enabled / human led service offering to a primarily technology based service offering (READ – MASSIVE OPERATING LEVERAGE) Opex costs should not increase in line with revenue going forward.
The following are IKS’s proprietary technology platforms –
- IKS EVE: This platform is designed for multi-channel patient access and patient engagement solutions.
- Optimix: A proprietary workflow management platform specifically engineered for revenue optimization.
- Scribble (including Scribble Now, Scribble Swift, Scribble Pro, Scribble Transcribe): This is an AI-driven clinical documentation solution that improves efficiency through AI-generated clinical notes, this is an ambient audio to text documentation platform designed for precise capture of medical terminology, and provides end-to-end automation from audio capture to the final physician’s clinical note.
- IKS Stacks: A platform capable of scanning, identifying, and abstracting relevant data from incoming clinical documents.
- IKS AssuRx: This solution standardizes prescription renewal requests, thereby reducing administrative burdens on physicians.
- Dashboard: Provides clients with real-time access to critical financial data, including claims status, revenue trends, and accounts receivables.
Beyond these specific platforms, IKS Health employs Robotic Process Automation (RPA) to automate structured and repetitive tasks. A notable advancement in its technological strategy is the adoption of an “Agentic AI” approach, which is projected to achieve a high automation potential ranging from 40% to 80% resulting in reduced employee-related expenses and improved overall operating margins.
Furthermore, AI-driven solutions like Scribble and predictive analytics for denial prevention offer tangible benefits to clients, such as a reduction in denied claims and improved cash flow. This proactive, AI-first approach enables IKS to deliver superior outcomes, differentiating it from traditional RCM providers and solidifying its competitive edge.
Risks & Mitigation – As with all technology product based companies, there’s always a risk that someone else might come up with a better mouse trap. Given the amount of funding several startup’s are receiving in the industry for point solutions (ex – Scribe solutions etc.) it is only a matter of time before someone come’s up with a better product/solution. It is imperative therefore to understand the switching costs. Most of the competition so far are only focusing on one two or three problems faced by the industry, example RCM only, or scribing only etc. Very few offer the full gamut of 16 solutions that IKS offers. Furthermore, integration between these various point solutions do pose a problem. It is much more advantageous therefore to stick to a fully integrated IKS service offering & not switch to whatever is a greater & better point solution, not to mention the cost to re-train staff & physicians on any potentially newer/competing technology. It must also be mentioned that so far, IKS’s product offerings are the top 3 in the industry for almost all of the 16 vertical’s they have solutions for.
There are massive changes that are expected in the US healthcare industry, from reduced funding for Medicaid to changes in how Medicare reimbursements occur etc. While this could be a risk for IKS’s business, it is more of a risk for the entire industry. It is also uncertain how/when things are going to unfold so that is definitely a known unknown to keep an eye out for.
Final Thoughts – There is a ton more I can write about the company / this space, such as my personal financial projections going forward etc. etc. But the point of this initial note was just to get the conversation started & over the next several posts, dig deeper product wise on all 16, understanding the competitive dynamics, TAM & IKS’s positioning in each.
If I were to sum up the investment thesis in one line – IKS is a high growth, high RoE, highly cash generative, AI enabled tech company with a sticky customer base that is trying to garnish a lion’s share (150k/900k physicians in the US & growing) of the fragmented healthcare BPO industry.
Let’s get the conversation started & happy investing to all 
.
Disclosures - Invested. Less than 3% of my pf.
Usefull Links -
